Logo image
Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?
Journal article   Open access   Peer reviewed

Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?

Etienne Billette de Villemeur, Jack W. Scannell and Bruno Versaevel
Drug Discovery Today, Vol.27(11)
01/11/2022

Abstract

Biotechnology Development Externalities Outsourcing Pharmaceuticals Research
Research and development (R&D) outsourcing offers some obvious productivity benefits (e.g., access to new technology, variabilised costs, risk sharing, etc.). However, recent work in economics points to a productivity headwind at the level of the innovation ecosystem. The market for technologies with economies of scope and knowledge spillovers (those with the biggest impact on industry economics and social welfare) has structural features that allow customers to capture a disproportionate share of economic value and transfer a disproportionate share of economic risk to technology providers, even though the providers aim to maximise profit. This reduces the incentives to invest in new ventures that specialise in the most promising early-stage projects. Therefore, near-term gains from R&D outsourcing can be offset by slower innovation in the long run.
pdf
DDT_Versaevel_202211DownloadView
Open Access CC BY V4.0
url
https://doi.org/10.1016/j.drudis.2022.08.001View
Published (Version of record) Open

Metrics

1 File views/ downloads
18 Record Views

Details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this contribution

Collaboration types
Domestic collaboration
International collaboration
Citation topics
6 Social Sciences
6.3 Management
6.3.2 Innovation Strategies
Web of Science research areas
Pharmacology & Pharmacy
Logo image